Janne PA, Goto Y, Kubo T, Ninomiya K, et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer. J Thorac Oncol 2025 Jul 30:S1556-0864(25)00981.
PMID: 40749900